{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:43Z","timestamp":1790526403701,"version":"4.1.0"},"reference-count":221,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV-19-08-00144"],"award-info":[{"award-number":["NV-19-08-00144"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GA20-25308S"],"award-info":[{"award-number":["GA20-25308S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","award":["GAUK-748318"],"award-info":[{"award-number":["GAUK-748318"]}],"id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory disease or experience lymphoma relapse. Chemotherapy-based salvage therapy of relapsed\/refractory NHL is, however, capable of re-inducing long-term remissions only in a minority of patients. Immunotherapy-based approaches, including bispecific antibodies, immune checkpoint inhibitors and genetically engineered T-cells carrying chimeric antigen receptors, single-agent or in combination with therapeutic monoclonal antibodies, immunomodulatory agents, chemotherapy or targeted agents demonstrated unprecedented clinical activity in heavily-pretreated patients with NHL, including chemotherapy-refractory cases with complex karyotype changes and other adverse prognostic factors. In this review, we recapitulate currently used immunotherapy modalities in NHL and discuss future perspectives of combinatorial immunotherapy strategies, including patient-tailored approaches.<\/jats:p>","DOI":"10.3390\/vaccines8040708","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T09:16:49Z","timestamp":1606468609000},"page":"708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Current Immunotherapy Approaches in Non-Hodgkin Lymphomas"],"prefix":"10.3390","volume":"8","author":[{"given":"Robert","family":"Pytlik","sequence":"first","affiliation":[{"name":"Institute of Haematology and Blood Transfusion, 128 00 Prague, Czech Republic"},{"name":"First Department of Internal Medicine-Hematology, University General Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, 110 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-1692","authenticated-orcid":false,"given":"Kamila","family":"Polgarova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, University General Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, 110 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Karolova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, University General Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, 110 00 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, University General Hospital in Prague and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, 110 00 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2214\/ajr.96.1.166","article-title":"Combined therapy in malignant lymphoma","volume":"96","author":"Bronstein","year":"1966","journal-title":"Am. J. Roentgenol. Radium Ther. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.2013.786698","article-title":"Rituximab in the treatment of non-Hodgkin\u2019s lymphoma--a critical evaluation of randomized controlled trials","volume":"13","author":"Griffin","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","first-page":"428253","article-title":"Monoclonal antibodies for non-Hodgkin\u2019s lymphoma: State of the art and perspectives","volume":"2010","author":"Motta","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vidarsson, G., Dekkers, G., and Rispens, T. (2014). IgG Subclasses and Allotypes: From Structure to Effector Functions. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00520"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12026-014-8542-z","article-title":"Complement in monoclonal antibody therapy of cancer","volume":"59","author":"Rogers","year":"2014","journal-title":"Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a \u201cvaccinal effect\u201d of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"key":"ref_9","first-page":"1","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saunders, K.O. (2019). Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01296"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.seminhematol.2008.02.005","article-title":"Monoclonal antibodies in lymphoma: The first decade","volume":"45","author":"Link","year":"2008","journal-title":"Semin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: A randomised, double-blind, parallel-group, non-inferiority phase 3 trial","volume":"4","author":"Kim","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: Phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1200\/jco.2013.31.15_suppl.7045","article-title":"MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab","volume":"31","author":"Hamadani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2011-07-365437","article-title":"Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial","volume":"119","author":"Lepretre","year":"2012","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: Final analysis of a prospective phase II trial","volume":"92","author":"Binder","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1080\/10428194.2018.1562184","article-title":"Phase 1\/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas","volume":"60","author":"Roswarski","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_35","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific Antibodies in the Treatment of Hematologic Malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: Design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00262-007-0333-0","article-title":"Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells","volume":"56","author":"Moldenhauer","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"287ra270","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: A historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cts.12535","article-title":"A Preclinical Population Pharmacokinetic Model for Anti-CD20\/CD3 T-Cell-Dependent Bispecific Antibodies","volume":"11","author":"Ferl","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL)","volume":"37","author":"Bartlett","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e1203498","DOI":"10.1080\/2162402X.2016.1203498","article-title":"CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors","volume":"5","author":"Bacac","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.59_2629","article-title":"Cd20-Tcb (Rg6026), A Novel \u201c2:1\u201d Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed\/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"37","author":"Dickinson","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2018-99-110207","article-title":"CD20-Tcb (RG6026), a Novel \u201c2:1\u201d Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed\/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma: Preliminary Results from a Phase I First in Human Trial","volume":"132","author":"Hutchings","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Chen, Z., Yang, Y., Liu, L.L., and Lundqvist, A. (2019). Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers, 11.","DOI":"10.3390\/cancers11071040"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.leu.2404499","article-title":"CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases","volume":"21","author":"Grzywacz","year":"2007","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102042","DOI":"10.1016\/j.ctrv.2020.102042","article-title":"Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies","volume":"88","author":"Tun","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kuzume, A., Chi, S., Yamauchi, N., and Minami, Y. (2020). Immune-Checkpoint Blockade Therapy in Lymphoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155456"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.21147\/j.issn.1000-9604.2020.03.03","article-title":"Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives","volume":"32","author":"Lin","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: Update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 Blockade in Mediastinal Gray-Zone Lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: A nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of Efficacy of Pembrolizumab between Epstein-Barr VirusPositive and Negative Relapsed or Refractory Non-Hodgkin Lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Armand, P., Janssens, A.M., Gritti, G., Radford, J., Timmerman, J.M., Pinto, A., Mercadal Vilchez, S., Johnson, P.W.M., Cunningham, D., and Leonard, J.P. (2020). Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma. Blood.","DOI":"10.1182\/blood.2019004753"},{"key":"ref_89","first-page":"4055","article-title":"PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma","volume":"130","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-Human Study of Utomilumab, a 4-1BB\/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_98","unstructured":"Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., and H\u00fcsser, T. (2019). Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci. Transl. Med., 11."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","article-title":"Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The Interaction Between Signal Regulatory Protein Alpha (SIRP\u03b1) and CD47: Structure, Function, and Therapeutic Target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_104","first-page":"4116","article-title":"TTI-621 (SIRP\u03b1Fc), an Immune Checkpoint Inhibitor Blocking the CD47 \u201cDo Not Eat\u201d Signal, Induces Objective Responses in Patients with Advanced, Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"130","author":"Ansell","year":"2017","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ejca.2018.07.297","article-title":"Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRP\u03b1Fc) induces antitumor activity in patients with relapsed\/refractory mycosis fungoides and Sezary syndrome: Interim results of a multicenter Phase 1 trial","volume":"101","author":"Querfeld","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrd3052","article-title":"Challenges with advanced therapy medicinal products and how to meet them","volume":"9","author":"Schneider","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Jackson, Z., Roe, A., Sharma, A.A., Lopes, F.B.T.P., Talla, A., Kleinsorge-Block, S., Zamborsky, K., Schiavone, J., Manjappa, S., and Schauner, R. (2020). Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01941"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","article-title":"Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides","volume":"64","author":"Romeo","year":"1991","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","article-title":"T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins","volume":"88","author":"Letourneur","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","article-title":"CAR T Cells: A Snapshot on the Growing Options to Design a CAR","volume":"3","author":"Holzinger","year":"2019","journal-title":"Hemasphere"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/gt.2016.48","article-title":"A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv","volume":"23","author":"Faitschuk","year":"2016","journal-title":"Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2217\/fon-2017-0102","article-title":"Exploiting natural killer group 2D receptors for CAR T-cell therapy","volume":"13","author":"Demoulin","year":"2017","journal-title":"Future Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e1368604","DOI":"10.1080\/2162402X.2017.1368604","article-title":"mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting","volume":"7","author":"Lohmueller","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12216","article-title":"CD3\u03b6-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: Implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Salter, A.I., Ivey, R.G., Kennedy, J.J., Voillet, V., Rajan, A., Alderman, E.J., Voytovich, U.J., Lin, C., Sommermeyer, D., and Liu, L. (2018). Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal, 11.","DOI":"10.1126\/scisignal.aat6753"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","article-title":"In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia","volume":"26","author":"Cheng","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Karlsson, H., Svensson, E., Gigg, C., Jarvius, M., Olsson-Str\u00f6mberg, U., Savoldo, B., Dotti, G., and Loskog, A. (2015). Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144787"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Guedan, S., Posey, A.D., Shaw, C., Wing, A., Da, T., Patel, P.R., McGettigan, S.E., Casado-Medrano, V., Kawalekar, O.U., and Uribe-Herranz, M. (2018). Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, 3.","DOI":"10.1172\/jci.insight.96976"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Sesques, P., Ferrant, E., Safar, V., Wallet, F., Tordo, J., Dhomps, A., Karlin, L., Brisou, G., Vercasson, M., and Hospital-Gustem, C. (2020). Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am. J. Hematol.","DOI":"10.1002\/ajh.25951"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"(2020). CAR T-Cell Therapy Shows Durable Responses in Indolent NHL. Oncologist, 25, S6\u2013S7.","DOI":"10.1634\/theoncologist.2020-0559"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019","volume":"7","author":"Lemal","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jh482","article-title":"Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review","volume":"8","author":"Sardar","year":"2019","journal-title":"J. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ramos, C.A., Grover, N.S., Beaven, A.W., Lulla, P.D., Wu, M.F., Ivanova, A., Wang, T., Shea, T.C., Rooney, C.M., and Dittus, C. (2020). Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.20.01342"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Chen, X., Tian, Y., Li, F., Zhao, X., Liu, J., Yao, C., and Zhang, Y. (2020). Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-001150"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/bloodadvances.2020002292","article-title":"Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy","volume":"4","author":"Chow","year":"2020","journal-title":"Blood Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3389\/fimmu.2018.01955","article-title":"PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma","volume":"9","author":"Rataj","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood.V91.10.3850","article-title":"Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo","volume":"91","author":"Nagashima","year":"1998","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: Implications for gene therapy","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zheng, H., and Diao, Y. (2019). Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020317"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00281-018-0721-x","article-title":"Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells","volume":"41","author":"Saetersmoen","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11899-019-00536-6","article-title":"IMiDs New and Old","volume":"14","author":"Yamshon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: A multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.3324\/haematol.2016.147256","article-title":"Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): A multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41375-018-0282-y","article-title":"Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse\/refractory aggressive lymphoma: A phase II LYSA study","volume":"33","author":"Houot","year":"2019","journal-title":"Leukemia"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/annonc\/mdz142","article-title":"Maintenance lenalidomide in primary CNS lymphoma","volume":"30","author":"Rubenstein","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2019002395","article-title":"Avadomide monotherapy in relapsed\/refractory DLBCL: Safety, efficacy, and a predictive gene classifier","volume":"135","author":"Carpio","year":"2020","journal-title":"Blood"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1016\/S2352-3026(20)30208-8","article-title":"Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): A multicentre, dose escalation and expansion phase 1 study","volume":"7","author":"Michot","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.clml.2019.09.604","article-title":"Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience","volume":"19","author":"Patel","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_198","first-page":"16","article-title":"General aspects of cytokine-release syndrome: Timing and incidence of symptoms","volume":"25","author":"Jeyarajah","year":"1993","journal-title":"Transplant. Proc."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab Hypersensitivity: From Clinical Presentation to Management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","article-title":"Strategies in the management of alemtuzumab-related side effects","volume":"33","author":"Osterborg","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-013-0066-x","article-title":"Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy","volume":"28","author":"Mezzano","year":"2014","journal-title":"BioDrugs"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Vani, V., Regge, D., Cappello, G., Gabelloni, M., and Neri, E. (2020). Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics, 10.","DOI":"10.3390\/diagnostics10040216"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/eji.1830241235","article-title":"Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis","volume":"24","author":"Wagner","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal. Transduct Target. Ther."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","article-title":"Management of cytokine release syndrome related to CAR-T cell therapy","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Med."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Huarte, E., O\u2019Connor, R.S., Peel, M.T., Nunez-Cruz, S., Leferovich, J., Juvekar, A., Yang, Y.O., Truong, L., Huang, T., and Naim, A. (2020). Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-20-1739"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema","volume":"77","author":"Torre","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:19Z","timestamp":1760179099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":221,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040708"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040708","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]}}}